XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value of financial instruments and marketable securities - Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2021
USD ($)
fund
$ / shares
Jan. 31, 2020
USD ($)
$ / shares
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
shares
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
Apr. 29, 2020
Sep. 30, 2019
USD ($)
$ / shares
May 31, 2019
USD ($)
$ / shares
Aug. 31, 2015
USD ($)
$ / shares
Financial assets and liabilities measured at fair value on recurring basis                      
Write downs of available for sale debt securities     $ 0   $ 0            
Realized gain (loss) from sale of marketable securities     0.0 $ 200,000 700,000 $ 200,000          
Increase in allowance for credit losses     0 0 0 0          
Unrealized gain (loss) on ClearPoint Equity Investment     (2,700,000) (100,000) 4,110,000 (1,600,000)          
Marketable securities - equity investments     24,700,000   24,700,000   $ 20,500,000        
Purchase of convertible debt investment   $ 10,000,000.0       10,000,000          
Conversion price per share (in dollars per share) | $ / shares   $ 6.00                  
Debt instrument, convertible, period   5 years                  
Unrealized loss     3,500,000     700,000          
Unrealized gain on convertible note       2,100,000 4,300,000            
Fair value of convertible debt     33,600,000   33,600,000   29,300,000        
Purchase of marketable securities - equity investments $ 200,000,000.0       200,000,000            
Number of mutual funds invested in | fund 2                    
Unrealized gains on equity investments     1,000,000.0   694,000            
Transfers of assets measured between Level 1, Level 2, and Level 3     0   0   0        
Non-cash stock consideration, acquisition           42,869,000          
Operating Expenses     215,169,000 262,512,000 431,258,000 423,762,000          
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset     (700,000) $ (7,680,000) (800,000) $ (8,580,000)          
Common stock                      
Financial assets and liabilities measured at fair value on recurring basis                      
Issuance of common stock related to rights exchange (in shares) | shares       2,821,176   2,821,176          
3.00% Convertible senior notes due 2022 | Convertible debt                      
Financial assets and liabilities measured at fair value on recurring basis                      
Principal     150,000,000   150,000,000   150,000,000       $ 150,000,000.0
Interest rate ( as a percent )                     3.00%
Fair value of convertible notes     160,600,000   160,600,000   193,200,000        
Conversion price per share (in dollars per share) | $ / shares                     $ 56.34
1.50% Convertible senior notes due 2026 | Convertible debt                      
Financial assets and liabilities measured at fair value on recurring basis                      
Principal     $ 287,500,000   $ 287,500,000   287,500,000   $ 287,500,000    
Interest rate ( as a percent )     1.50%   1.50%       1.50%    
Fair value of convertible notes     $ 312,000,000.0   $ 312,000,000.0   394,900,000        
Conversion price per share (in dollars per share) | $ / shares                 $ 52.52    
Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Development milestone payments which the entity is obligated to pay     $ 40,000,000.0   $ 40,000,000.0            
Agilis | Minimum                      
Financial assets and liabilities measured at fair value on recurring basis                      
Product sales (as a percent)     2.00%   2.00%     2.00%      
Agilis | Maximum                      
Financial assets and liabilities measured at fair value on recurring basis                      
Product sales (as a percent)     6.00%   6.00%     6.00%      
Development milestone payments which the entity is obligated to pay     $ 60,000,000.0   $ 60,000,000.0            
Priority review voucher amount         535,000,000.0            
Net sales amount     150,000,000.0   150,000,000.0            
Recurring basis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Fair value of convertible debt     $ 33,578,000   $ 33,578,000   $ 29,252,000        
Common stock                      
Financial assets and liabilities measured at fair value on recurring basis                      
Shares purchased $ 100,000                 $ 4,000,000.0  
Share price (in USD per share) | $ / shares $ 23.50                 $ 3.10  
Development and Regulatory Milestone | Probability of Success | Weighted Average | Contingent Consideration Payable                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement     42   42            
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Weighted Average | Contingent Consideration Payable                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement     3.2   3.2            
Net Sales Milestones and Royalties | Probability of Success | Weighted Average | Contingent Consideration Payable                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement     48   48            
Net Sales Milestones and Royalties | Agilis | Measurement Input, Discount Rate | Contingent Consideration Payable                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement     0.120   0.120